Mobile website
Archive > Volume 30 Issue 11 > 2023,30(11):981-986. DOI:10.3872/j.issn.1007-385X.2023.11.007 Prev Next
Clinical Research
Effect of Fuzheng formulas on the level of soluble immune checkpoint protein molecules in peripheral blood of patients with advanced NSCLC and its clinical significance
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective: To observe the effect of Fuzheng formulas on the peripheral blood levels of 12 soluble immune checkpoint molecules in patients with advanced non-small cell lung cancer (NSCLC) treated with third-line therapy, and to analyze the relationship between the baseline level of soluble immune checkpoints and the progression-free survival (PFS) of NSCLC patients. Methods: A total of 72 patients with advanced NSCLC who received third-line treatment (Fuzheng formulas combined with standard Western medicine treatment regimen) in the Department of Oncology, Longhua Hospital from October 2020 to April 2023 were enrolled. The LEGENDplexTM multi-factor kit was used to detect the expression level of soluble immune checkpoint molecules before and after 4 cycles of treatment, and the correlation between their baseline levels and PFS prognosis was analyzed. Results: After 4 cycles of treatment, sCD137, sTGF- β1, sPD-L1, sPD-L2 and other indicators were significantly decreased (P<0.05 or P<0.01). Kaplan-Meier survival analysis showed that the PFS of patients with high sPD-L2 level was shorter than that of patients with low sPD-L2 level (P<0.05). COX multivariate analysis showed that sPD-L2 expression level was an independent impact factor for PFS in advanced NSCLC patients treated with third-line therapy (P<0.05). Conclusion: Fuzheng formulas have a certain regulatory effect on the levels of soluble immune checkpoint molecules. A high level of sPD-L2 indicates shorter PFS in patients with advanced NSCLC, and sPD-L2 may be an independent impact factor for PFS in advanced NSCLC patients undergoing third-line treatment.
Keywords:
Project Supported:
Clc Number:
